Medline (MDLN) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Medline is the larger company by market cap ($48.05 billion vs $31.75 billion), about 1.5 times the size. On valuation, ResMed trades at a lower forward P/E (17.1x vs 22.6x for Medline). ResMed pays a dividend yielding 1.06%, while Medline does not currently pay one.
ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 4.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDLN | RMD |
|---|---|---|
| Share price | $35.71 | $225.79 |
| Market cap | $48.05B | $31.75B |
| 1-day change | +0.73% | -0.08% |
| YTD return | -15.60% | -6.18% |
| 1-year return | — | -20.23% |
| 5-year return | — | -11.55% |
| P/E ratio (TTM) | 89.27 | 21.65 |
| Forward P/E | 22.65 | 17.07 |
| EPS (TTM) | $0.40 | $10.43 |
| Dividend yield | 0.00% | 1.06% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $28.43B | $5.65B |
| Revenue growth (YoY) | — | +9.85% |
| Net income (latest FY) | $1.16B | $1.52B |
| Gross margin | 26.44% | 61.06% |
| Operating margin | 7.78% | 33.37% |
| Net margin | 4.08% | 26.94% |
| 52-week high | $50.88 | $284.05 |
| 52-week low | $31.49 | $180.27 |
| Distance from 52-week high | -29.81% | -20.51% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +24.61% | +10.82% |
| Average volume | 7.54M | 1.34M |
| Shares outstanding | 877.35M | 140.64M |
| Employees | 45,000 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline trades at a higher earnings multiple (89.3x vs 21.6x trailing P/E).
- ResMed offers a meaningfully higher dividend yield (1.06% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 4.1 cents for Medline.
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
MDLN vs RMD FAQ
Which is bigger, Medline or ResMed?
Medline (MDLN) is larger, with a market capitalization of $48.05B compared with $31.75B for ResMed (RMD).
Which has the lower P/E ratio, MDLN or RMD?
RMD has the lower trailing P/E at 21.6, versus 89.3 for MDLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Medline or ResMed?
ResMed pays a dividend yielding 1.06%, while Medline does not currently pay a regular dividend.
Are Medline and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.